M Farnier

Summary

Country: France

Publications

  1. doi request reprint PCSK9: From discovery to therapeutic applications
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France Electronic address
    Arch Cardiovasc Dis 107:58-66. 2014
  2. doi request reprint Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia
    Michel Farnier
    Point Medical, 21000 Dijon, France
    Atherosclerosis 229:415-22. 2013
  3. doi request reprint PCSK9 inhibitors
    Michel Farnier
    Department of Lipidology, Point Medical, Dijon, France
    Curr Opin Lipidol 24:251-8. 2013
  4. doi request reprint Severe familial hypercholesterolaemia: current and future management
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Arch Cardiovasc Dis 105:656-65. 2012
  5. doi request reprint Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease
    Michel Farnier
    Point Medical, Dijon, France
    Diab Vasc Dis Res 9:205-15. 2012
  6. doi request reprint Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Expert Rev Cardiovasc Ther 10:565-75. 2012
  7. doi request reprint Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials
    Michel Farnier
    Point Mdical, Dijon, France
    Clin Drug Investig 32:281-91. 2012
  8. pmc Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
    Margus Viigimaa
    Tallinn University of Technology, Technomedicum, Ehitajate St, 5, 19086 Tallinn, Estonia
    Lipids Health Dis 9:127. 2010
  9. ncbi request reprint [Dyslipidemia and abdominal obesity: therapeutic approaches (Part II)]
    M Farnier
    Point Medical, Dijon
    Arch Mal Coeur Vaiss 100:985-7, 990-1. 2007
  10. doi request reprint Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients
    Michel Farnier
    Point Medical, Rond Point de Nation, 21000 Dijon, France
    J Clin Lipidol 5:179-87. 2011

Detail Information

Publications41

  1. doi request reprint PCSK9: From discovery to therapeutic applications
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France Electronic address
    Arch Cardiovasc Dis 107:58-66. 2014
    ..Large phase III programmes are ongoing to evaluate the long-term efficacy and safety of these very promising new agents...
  2. doi request reprint Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia
    Michel Farnier
    Point Medical, 21000 Dijon, France
    Atherosclerosis 229:415-22. 2013
    ....
  3. doi request reprint PCSK9 inhibitors
    Michel Farnier
    Department of Lipidology, Point Medical, Dijon, France
    Curr Opin Lipidol 24:251-8. 2013
    ..To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9...
  4. doi request reprint Severe familial hypercholesterolaemia: current and future management
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Arch Cardiovasc Dis 105:656-65. 2012
    ..In this article, we review the recommendations for diagnosis and treatment of severe familial hypercholesterolaemia and the agents currently available or under development...
  5. doi request reprint Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease
    Michel Farnier
    Point Medical, Dijon, France
    Diab Vasc Dis Res 9:205-15. 2012
    ....
  6. doi request reprint Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Expert Rev Cardiovasc Ther 10:565-75. 2012
    ..Whether Pravafenix confers additional cardiovascular benefits in high-risk patients treated with a statin remains to be determined...
  7. doi request reprint Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials
    Michel Farnier
    Point Mdical, Dijon, France
    Clin Drug Investig 32:281-91. 2012
    ..However, some safety concerns, particularly an increased risk of myopathy, have been reported when these drugs are taken together...
  8. pmc Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
    Margus Viigimaa
    Tallinn University of Technology, Technomedicum, Ehitajate St, 5, 19086 Tallinn, Estonia
    Lipids Health Dis 9:127. 2010
    ..This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization...
  9. ncbi request reprint [Dyslipidemia and abdominal obesity: therapeutic approaches (Part II)]
    M Farnier
    Point Medical, Dijon
    Arch Mal Coeur Vaiss 100:985-7, 990-1. 2007
    ..New therapeutic approaches are aimed directly at the excess visceral adipose tissue, and the CB1 receptor blockers are particularly promising for improving the overall lipid profile for patients with abdominal obesity...
  10. doi request reprint Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients
    Michel Farnier
    Point Medical, Rond Point de Nation, 21000 Dijon, France
    J Clin Lipidol 5:179-87. 2011
    ..This post-hoc analysis studied the correlation between these parameters in patients with mixed dyslipidemia before and after receiving lipid-lowering treatment...
  11. doi request reprint VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
    Michel Farnier
    Point Medical, Dijon, France
    J Lipid Res 49:2641-7. 2008
    ..Thus, ezetimibe/simvastatin + fenofibrate produced favorable effects on atherogenic lipoprotein subclasses in patients with mixed hyperlipidemia...
  12. doi request reprint The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications
    Michel Farnier
    Point Medical, Dijon, France
    Am J Cardiovasc Drugs 11:145-52. 2011
    ....
  13. pmc Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
    Michel Farnier
    Point Medical, Dijon, France
    Vasc Health Risk Manag 4:991-1000. 2008
    ..However, the role of fenofibrate-statin therapy and of other therapies involving fenofibrate in cardiovascular risk reduction strategies remains to be established...
  14. doi request reprint Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study
    M Farnier
    Point Medical, Rond Point de Nation, Dijon, France
    Int J Clin Pract 63:547-59. 2009
    ..To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg vs. rosuvastatin (ROSUVA) 10 mg...
  15. doi request reprint [How to manage lipid profiles and their interpretation in patients with coronary heart disease?]
    Michel Farnier
    Endocrinologie maladies métaboliques, Point Medical, F 21000, Dijon, France
    Presse Med 38:958-63. 2009
    ..In coronary patients treated with a statin, management of abnormal levels of triglycerides and HDL-cholesterol is important to minimize the risk of recurrence...
  16. doi request reprint Safety review of combination drugs for hyperlipidemia
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Expert Opin Drug Saf 10:363-71. 2011
    ..The long-term safety and tolerability of these combination therapies are key determinants for good compliance and cardiovascular benefits...
  17. ncbi request reprint [Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)]
    M Farnier
    Point Medical, Dijon
    Arch Mal Coeur Vaiss 100:979-84. 2007
    ..This excess adipose tissue seems to be the direct origin of the dyslipidemia associated with abdominal obesity, causing more free fatty acids to flow into the liver and contributing to insulin resistance...
  18. ncbi request reprint Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Fundam Clin Pharmacol 21:27-8. 2007
    ..Ezetimibe/simvastatin offers an important treatment alternative to patients who respond inadequately even to high-dose statin therapy...
  19. doi request reprint Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study
    Michel Farnier
    Point Medical, Dijon, France
    Clin Ther 33:1-12. 2011
    ..This study was designed to obtain regulatory approval of a fenofibrate/pravastatin 160/40 mg fixed-dose combination (FDC) capsule...
  20. ncbi request reprint [What about HDL cholesterol?]
    Michel Farnier
    Le Point médical, 21000 Dijon
    Rev Prat 61:1117-20. 2011
    ..Until now, nicotinic acid is the most effective drug. All the new therapeutic strategies acting on HDL should be validated by cardiovascular clinical trials...
  21. pmc Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
    Michel Farnier
    Point Medical, Dijon, France
    Lipids Health Dis 10:212. 2011
    ..Fibrates have been reported to cause paradoxical decreases in HDL-C in certain patients...
  22. doi request reprint Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy
    Michel Farnier
    Point Medical, Dijon, France
    Curr Med Res Opin 27:2165-73. 2011
    ..To assess the long-term safety and efficacy of a fenofibrate/pravastatin 160/40 mg fixed-dose combination in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy...
  23. ncbi request reprint Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: The ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey
    M Farnier
    Point Medical, Dijon, France
    Int J Clin Pract 60:1166-71. 2006
    ..Our findings indicate that in France, the prevalence of low HDL-C remains relatively high, particularly for patients with obesity and HTG...
  24. ncbi request reprint Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia
    Michel Farnier
    Point Medical, Dijon, France
    Am Heart J 153:335.e1-8. 2007
    ..Mixed hyperlipidemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and TG-rich lipoprotein levels...
  25. ncbi request reprint Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Expert Opin Pharmacother 8:1345-52. 2007
    ..Nevertheless, this combination therapy of ezetimibe plus fenofibrate seems particularly useful for patients with a poor response or intolerance to statin monotherapy...
  26. ncbi request reprint Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group
    M Farnier
    Point Medical, Dijon, France
    Am J Cardiol 85:53-7. 2000
    ..In conclusion, the addition of fluvastatin to micronized fenofibrate results in substantial improvement in atherogenic plasma lipids and is well tolerated...
  27. ncbi request reprint Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Int J Cardiol 102:327-32. 2005
    ..60 mmol/l (100 mg/dl) in hypercholesterolemic patients with coronary heart disease (CHD)...
  28. ncbi request reprint [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]
    M Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon
    Arch Mal Coeur Vaiss 100:569-81. 2007
  29. doi request reprint Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy
    Michel Farnier
    Point Medical, Dijon, France
    Am J Cardiol 106:787-92. 2010
    ....
  30. ncbi request reprint Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon F 21 000, France
    Eur Heart J 26:897-905. 2005
    ..To examine the efficacy and safety of coadministered ezetimibe (EZE) with fenofibrate (FENO) in patients with mixed hyperlipidaemia...
  31. ncbi request reprint Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)
    Michel Farnier
    Point Medical, Dijon, France
    Am J Cardiol 92:794-7. 2003
    ..The combination of fluvastatin and fibrates was well tolerated with no major safety concerns...
  32. ncbi request reprint Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment
    M Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Am J Cardiol 82:47J-51J. 1998
    ..This study demonstrated that cerivastatin is a safe, well-tolerated, and effective treatment for lowering elevated LDL cholesterol and triglycerides in patients with mixed hyperlipidemia...
  33. ncbi request reprint Diabetes: statins, fibrates, or both?
    M Farnier
    Point Medical, Rond Point de la Nation, Dijon, F 21000, France
    Curr Atheroscler Rep 3:19-28. 2001
    ..If lipid target values are not reached, a combination therapy can then be initiated, with close follow-up of potential side effects...
  34. ncbi request reprint Ezetimibe in hypercholesterolaemia
    M Farnier
    Point Medical, Dijon, France
    Int J Clin Pract 56:611-4. 2002
    ..This additive 18% reduction in LDL-C is achieved in one step compared with the three steps necessary with statin monotherapy...
  35. ncbi request reprint Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Am J Cardiovasc Drugs 3:169-78. 2003
    ....
  36. ncbi request reprint Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil)
    Michel Farnier
    Point Medical, Dijon, France
    Am J Cardiol 91:238-40. 2003
  37. ncbi request reprint Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
    James M McKenney
    National Clinical Research Inc, Richmond, Virginia 23294, USA
    J Am Coll Cardiol 47:1584-7. 2006
    ..This study sought to determine the long-term safety and efficacy of co-administered fenofibrate (FENO) and ezetimibe (EZE) in patients with mixed hyperlipidemia...
  38. doi request reprint Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
    Diane L Tribble
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Metabolism 57:796-801. 2008
    ....
  39. ncbi request reprint [New antilipemics: prospects]
    Michel Farnier
    Therapie 58:97-105. 2003
    ..Finally, the discovery of new specific lipoprotein receptors, such as the ABCA1 and SRB1 receptors, means that we can work towards developing new potential targets for pharmacological intervention...
  40. ncbi request reprint [Hypercholesterolemia, the future of drug associations]
    James Shepherd
    Presse Med 33:1141-2. 2004
  41. ncbi request reprint Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction
    Marianne Zeller
    Laboratory of Cardiovascular and Experimental Physiopathology and Pharmacology, Faculty of Medicine, University of Burgundy, Dijon, France
    Arch Intern Med 165:1192-8. 2005
    ....